Center on Health Equity and Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Partners

Press Releases

Product Approvals and Launches

Media

Clinical Spotlight

Enduring Webinars

Guidelines

Insights

Interviews

Microsites

News Network

OnLocation

Payer Perspectives

Peer Exchange

Podcasts

Post Conference Perspectives

Stakeholder Summit

Week in Review

Conferences

Conference Coverage

Conference Listing

Journals

Submit a Manuscript

All Journals

The American Journal of Managed Care

The American Journal of Accountable Care

Evidence-Based Oncology

Supplements and Featured Publications

Compendia

ALL/AML

Alopecia

Asthma

Atopic Dermatitis

Autoimmune

Biosimilars

Breast Cancer

CLL/SLL

COPD

COVID-19

Cardiovascular

Colorectal Cancer

DLBCL

Dermatology

Diabetes

Duchenne Muscular Dystrophy

Employers

Gastroenterology

Gene Therapy

Graft-vs-Host Disease (GVHD)

Heart Failure

Hemophilia

Idiopathic Pulmonary Fibrosis

Immuno-Oncology

Immunology

Leukemia and Lymphoma

Liver Cancer

Lung Cancer

Medicare

Mental Health

Multiple Myeloma

Multiple Sclerosis

Myasthenia Gravis

Myelodysplastic Syndromes

Myeloproliferative Neoplasms (MPN)

Non–Small Cell Lung Cancer

Obesity

Oncology

Ophthalmology

Ovarian Cancer

Population Health

Psoriasis

Pulmonary Arterial Hypertension

Rare Blood

Reimbursement

Skin Cancer

Sleep

Soft Tissue Sarcoma

Type 1 Diabetes

Events

Upcoming Webinars

CME/CE

Resources

Exclusive Content

Formulary Central

Interactive Tools

Subscribe

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Articles

A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.

Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Men who have sex with men (MSM) who are HIV-negative reported interest in an injectable pre-exposure prophylaxis (PrEP) that lasted longer than the daily pill, regardless of cost or coverage.

MSM Would Prefer Injectable, Long-Acting PrEP Over Daily Pill

Researchers addressed the impact of long-term coverage of telemedicine, following concerns that it will increase spending and hurt health care quality. 

How Telemedicine Has Impacted Medicare Utilization, Spending, and Quality of Care 

A large cohort study demonstrated the validity and reliability of single-channel electro-oculography (EOG) for sleep-stage classification. 

Single-Channel EOG Shown to Be Reliable for Automatic Sleep Staging in Various Sleep Disorders

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About Us

Contact

Editorial Staff

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Stakeholders

Academia

Health System

Payers

Providers

Topics

Institute for Value-Based Medicine

All Coverage

Event Coverage

About AJMC

AJMC Journals

Anniversary

Author Forms

Authors

Nominate a Rising Leader

1rem

Current Therapeutic Options and Treatments in Development for the Management of Primary Open-Angle Glaucoma

Participating Faculty 